Sector
PharmaceuticalsOpen
₹374.85Prev. Close
₹379.15Turnover(Lac.)
₹650.41Day's High
₹377.85Day's Low
₹371.452 Week's High
₹464.7552 Week's Low
₹294.3Book Value
₹103.69Face Value
₹2Mkt Cap (₹ Cr.)
4,633.64P/E
51EPS
7.37Divi. Yield
0.37Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 24.66 | 24.66 | 24.66 | 24.66 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,162.93 | 1,108.83 | 1,043.35 | 908.76 |
Net Worth | 1,187.59 | 1,133.49 | 1,068.01 | 933.42 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 1,720.43 | 1,507.26 | 1,296.09 | 1,013.93 |
yoy growth (%) | 14.14 | 16.29 | 27.82 | 9.53 |
Raw materials | -908.37 | -776.32 | -698.97 | -509.37 |
As % of sales | 52.79 | 51.5 | 53.92 | 50.23 |
Employee costs | -164.31 | -156.56 | -128.05 | -116.69 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 206.42 | 141.98 | 111.49 | 83.22 |
Depreciation | -85.24 | -82.46 | -85.59 | -69.14 |
Tax paid | -73.28 | -42.14 | -34.26 | -12.54 |
Working capital | 48.62 | 51.62 | 54.17 | 112.99 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.14 | 16.29 | 27.82 | 9.53 |
Op profit growth | 18.2 | 12.99 | 22.58 | 8.99 |
EBIT growth | 24.8 | 21.03 | 22.14 | 13.85 |
Net profit growth | 57.68 | 9.33 | 9.27 | 71.04 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 1,843.5 | 1,768.7 | 2,004.7 | 1,926.03 | 1,707.06 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,843.5 | 1,768.7 | 2,004.7 | 1,926.03 | 1,707.06 |
Other Operating Income | 16.3 | 15.9 | 18.33 | 16.69 | 13.38 |
Other Income | 5 | 2.5 | 5.41 | 4.89 | 4.98 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,687.4 | 94.51 | 4,04,767.81 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,725 | 80.79 | 1,78,467.89 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,502.8 | 24.63 | 1,21,323.17 | 1,485.4 | 1.07 | 4,254.47 | 397.42 |
Dr Reddys Laboratories Ltd DRREDDY | 1,362.7 | 21.27 | 1,13,756.67 | 1,200.7 | 0.59 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,258.8 | 57.91 | 1,10,340.1 | 474 | 0.98 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
Jai Hiremath
Vice Chairman & M.D.
Sameer Hiremath
Non-Exec & Non-Independent Dir
Sugandha Hiremath
Non-Exec & Non-Independent Dir
Amit B Kalyani
Non-Exec. & Independent Dir.
Shivani Bhasin Sachdeva
Company Sec. & Compli. Officer
Rajasekhar Reddy
Independent Director
Shrikrishna K. Adivarekar
Independent Director
Berjis Minoo Desai
Independent Director
V R Kaundinya
Independent Director
Ravi Brijmohan Kapoor
Independent Director
Ranjana Shivanand Salgaocar
Whole Time Director
Sarangan Suresh
717/718 Maker Chamber V,
7th Floor Nariman Point,
Maharashtra - 400021
Tel: 91-022-3926 7100/62770477
Website: http://www.hikal.com
Email: info@hikal.com
21 Shakil Niwas,
Mahakali Caves Road, Andheri (E),
Mumbai - 400 093
Tel: 91-22-28262920
Website: www.unisec.in
Email: info@unisec.in
Summary
Hikal Limited, incorporated on July 8, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specia...
Read More
Reports by Hikal Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.